Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback